Glenmark Pharmaceuticals receives FDA warning letter for Indore facility, commits to resolving compliance issues promptly.

We are just trying to regroup. One wrong move takes you back by four or five years,' Glenn Saldanha said, emphasising caution ...

Glenmark’s outlicensing deal with AbbVie for a novel drug for blood cancer under development sets a new course for the ...

But now, an Indian company has delivered a promising innovative anti-cancer drug molecule to deep-pocketed Big Pharma for ...

In March, the company had received approval from the drug regulator to import and sell sodium zirconium cyclosilicate powder ...

Glenmark’s progress with a cancer treatment shows the potential of Indian pharma to move from generics to drug discovery.

After two weeks of losses, the Nifty heads into a very important week amidst a rise in global trade tensions. However, the ...

Glenmark Pharmaceuticals Ltd is quoting at Rs 2214.7, up 1.54% on the day as on 12:49 IST on the NSE. The stock is up 57.28% in last one year as compared to a 1.88% jump in NIFTY and a 7.85% jump in ...

With the stock currently trading at Rs 2,225.80, Glenmark Pharma has shown a positive movement of 2.05% in today's session.

Glenmark Pharmaceuticals has announced that it received a warning letter from the U.S. Food and Drug Administration (FDA) for its manufacturing facility in Indore, Madhya Pradesh, India.

Promoter group entities of VIP Industries have agreed to sell up to 58 per cent stake in the luggage company to a consortium of Multiples private equity for ₹3,200 crore, according to an exchange ...

Glenmark Pharmaceuticals disclosed receiving a warning letter from the U.S. FDA for its Indore facility following a February inspection. The company clarified that the letter won’t impact existing ...